

**LEGISLATIVE BUDGET BOARD**  
**Austin, Texas**

**FISCAL NOTE, 85TH LEGISLATIVE REGULAR SESSION**

**April 14, 2017**

**TO:** Honorable Four Price, Chair, House Committee on Public Health

**FROM:** Ursula Parks, Director, Legislative Budget Board

**IN RE:** **HB3236** by Kacal (Relating to the costs associated with the provision of certain investigational drugs, biological products, and devices that are in clinical trials.), **As Introduced**

**No significant fiscal implication to the State is anticipated.**

The bill would amend the Health and Safety Code to allow a manufacturer to provide an investigational drug, biological product, or device to certain eligible patients and require the patient to pay costs related to the manufacture of the investigational drug, biological product, or device. The bill would take effect September 1, 2017. The Teacher Retirement System indicates that any costs associated with the bill could be absorbed within existing resources. Based on the LBB's analysis of the Employees Retirement System and the Health and Human Services Commission, duties and responsibilities associated with implementing the provisions of the bill could be accomplished by utilizing existing resources.

**Local Government Impact**

No significant fiscal implication to units of local government is anticipated.

**Source Agencies:** 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission

**LBB Staff:** UP, KCA, EP, MDI, TBo, TSI, KFa, CP